The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2020
Filed:
Nov. 24, 2017
Applicant:
Translational Drug Development, Llc, Scottsdale, AZ (US);
Inventors:
Tong Wang, Scottsdale, AZ (US);
Stephen Gately, Scottsdale, AZ (US);
Paul Gonzales, Scottsdale, AZ (US);
Assignee:
Translational Drug Development, LLC, Scottsdale, AZ (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61P 35/04 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 45/06 (2006.01); C07D 403/04 (2006.01); A61P 35/00 (2006.01); C07D 235/30 (2006.01); C07D 401/04 (2006.01); C07D 403/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 9/08 (2013.01); A61K 39/3955 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07D 235/30 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/804 (2018.08); A61K 2039/812 (2018.08);
Abstract
The present invention describes compositions, including pharmaceutical compositions, comprising an agent that binds members of the TNFRSF and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use include methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.